Characterization of glycan substrates accumulating in GM1 Gangliosidosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/203968 |
Resumo: | Introduction: GM1 gangliosidosis is a rare autosomal recessive genetic disorder caused by the disruption of the GLB1 gene that encodes β-galactosidase, a lysosomal hydrolase that removes β-linked galactose from the non-reducing end of glycans. Deficiency of this catabolic enzyme leads to the lysosomal accumulation of GM1 and its asialo derivative GA1 in β-galactosidase deficient patients and animal models. In addition to GM1 and GA1, there are other glycoconjugates that contain β-linked galactose whose metabolites are substrates for β-galactosidase. For example, a number of N-linked glycan structures that have galactose at their non-reducing end have been shown to accumulate in GM1 gangliosidosis patient tissues and biological fluids. Objective: In this study, we attempt to fully characterize the broad array of GLB1 substrates that require GLB1 for their lysosomal turnover. Results: Using tandem mass spectrometry and glycan reductive isotope labeling with data-dependent mass spectrometry, we have confirmed the accumulation of glycolipids (GM1 and GA1) and N-linked glycans with terminal beta-linked galactose. We have also discovered a novel set of core 1 and 2 O-linked glycan metabolites, many of which are part of structurally-related isobaric series that accumulate in disease. In the brain of GLB1 null mice, the levels of these glycan metabolites increased along with those of both GM1 and GA1 as a function of age. In addition to brain tissue, we found elevated levels of both N-linked and O-linked glycan metabolites in a number of peripheral tissues and in urine. Both brain and urine samples from human GM1 gangliosidosis patients exhibited large increases in steady state levels for the same glycan metabolites, demonstrating their correlation with this disease in humans as well. Conclusions: Our studies illustrate that GLB1 deficiency is not purely a ganglioside accumulation disorder, but instead a broad oligosaccharidosis that include representatives of many β-linked galactose containing glycans and glycoconjugates including glycolipids, N-linked glycans, and various O-linked glycans. Accounting for all β-galactosidase substrates that accumulate when this enzyme is deficient increases our understanding of this severe disorder by identifying metabolites that may drive certain aspects of the disease and may also serve as informative disease biomarkers to fully evaluate the efficacy of future therapies. |
id |
UFRGS-2_08674a4587d06f4a5a5dee5b6783484f |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/203968 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Lawrence, Rogervan Vleet, Jeremy L.Mangini, LinleyHarris, AdamMartin, Nathan T.Clark, Wyatt T.Chandriani, SanjayLeBowitz, Jonathan H.Giugliani, RobertoD'Azzo, AlessandraYogalingam, GouriCrawford, Brett E.2019-12-28T04:01:26Z20192214-4269http://hdl.handle.net/10183/203968001109125Introduction: GM1 gangliosidosis is a rare autosomal recessive genetic disorder caused by the disruption of the GLB1 gene that encodes β-galactosidase, a lysosomal hydrolase that removes β-linked galactose from the non-reducing end of glycans. Deficiency of this catabolic enzyme leads to the lysosomal accumulation of GM1 and its asialo derivative GA1 in β-galactosidase deficient patients and animal models. In addition to GM1 and GA1, there are other glycoconjugates that contain β-linked galactose whose metabolites are substrates for β-galactosidase. For example, a number of N-linked glycan structures that have galactose at their non-reducing end have been shown to accumulate in GM1 gangliosidosis patient tissues and biological fluids. Objective: In this study, we attempt to fully characterize the broad array of GLB1 substrates that require GLB1 for their lysosomal turnover. Results: Using tandem mass spectrometry and glycan reductive isotope labeling with data-dependent mass spectrometry, we have confirmed the accumulation of glycolipids (GM1 and GA1) and N-linked glycans with terminal beta-linked galactose. We have also discovered a novel set of core 1 and 2 O-linked glycan metabolites, many of which are part of structurally-related isobaric series that accumulate in disease. In the brain of GLB1 null mice, the levels of these glycan metabolites increased along with those of both GM1 and GA1 as a function of age. In addition to brain tissue, we found elevated levels of both N-linked and O-linked glycan metabolites in a number of peripheral tissues and in urine. Both brain and urine samples from human GM1 gangliosidosis patients exhibited large increases in steady state levels for the same glycan metabolites, demonstrating their correlation with this disease in humans as well. Conclusions: Our studies illustrate that GLB1 deficiency is not purely a ganglioside accumulation disorder, but instead a broad oligosaccharidosis that include representatives of many β-linked galactose containing glycans and glycoconjugates including glycolipids, N-linked glycans, and various O-linked glycans. Accounting for all β-galactosidase substrates that accumulate when this enzyme is deficient increases our understanding of this severe disorder by identifying metabolites that may drive certain aspects of the disease and may also serve as informative disease biomarkers to fully evaluate the efficacy of future therapies.application/pdfengMolecular genetics and metabolism reports. New York. vol. 21 (Dec. 2019), 100524, 17 f.Gangliosidose GM1beta-GalactosidaseBiomarcadoresGM1 gangliosidosisGLB1Beta-galactosidaseGlycan metabolitesDisease biomarkersGlycoanalysisCharacterization of glycan substrates accumulating in GM1 GangliosidosisEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001109125.pdf.txt001109125.pdf.txtExtracted Texttext/plain92435http://www.lume.ufrgs.br/bitstream/10183/203968/2/001109125.pdf.txt12c4d5094c6c76b42ea6c01b5fa048aeMD52ORIGINAL001109125.pdfTexto completo (inglês)application/pdf3035969http://www.lume.ufrgs.br/bitstream/10183/203968/1/001109125.pdfbd1d0098916bf1fda3132a982f53e23cMD5110183/2039682019-12-29 05:03:17.544717oai:www.lume.ufrgs.br:10183/203968Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2019-12-29T07:03:17Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
title |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
spellingShingle |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis Lawrence, Roger Gangliosidose GM1 beta-Galactosidase Biomarcadores GM1 gangliosidosis GLB1 Beta-galactosidase Glycan metabolites Disease biomarkers Glycoanalysis |
title_short |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
title_full |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
title_fullStr |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
title_full_unstemmed |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
title_sort |
Characterization of glycan substrates accumulating in GM1 Gangliosidosis |
author |
Lawrence, Roger |
author_facet |
Lawrence, Roger van Vleet, Jeremy L. Mangini, Linley Harris, Adam Martin, Nathan T. Clark, Wyatt T. Chandriani, Sanjay LeBowitz, Jonathan H. Giugliani, Roberto D'Azzo, Alessandra Yogalingam, Gouri Crawford, Brett E. |
author_role |
author |
author2 |
van Vleet, Jeremy L. Mangini, Linley Harris, Adam Martin, Nathan T. Clark, Wyatt T. Chandriani, Sanjay LeBowitz, Jonathan H. Giugliani, Roberto D'Azzo, Alessandra Yogalingam, Gouri Crawford, Brett E. |
author2_role |
author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Lawrence, Roger van Vleet, Jeremy L. Mangini, Linley Harris, Adam Martin, Nathan T. Clark, Wyatt T. Chandriani, Sanjay LeBowitz, Jonathan H. Giugliani, Roberto D'Azzo, Alessandra Yogalingam, Gouri Crawford, Brett E. |
dc.subject.por.fl_str_mv |
Gangliosidose GM1 beta-Galactosidase Biomarcadores |
topic |
Gangliosidose GM1 beta-Galactosidase Biomarcadores GM1 gangliosidosis GLB1 Beta-galactosidase Glycan metabolites Disease biomarkers Glycoanalysis |
dc.subject.eng.fl_str_mv |
GM1 gangliosidosis GLB1 Beta-galactosidase Glycan metabolites Disease biomarkers Glycoanalysis |
description |
Introduction: GM1 gangliosidosis is a rare autosomal recessive genetic disorder caused by the disruption of the GLB1 gene that encodes β-galactosidase, a lysosomal hydrolase that removes β-linked galactose from the non-reducing end of glycans. Deficiency of this catabolic enzyme leads to the lysosomal accumulation of GM1 and its asialo derivative GA1 in β-galactosidase deficient patients and animal models. In addition to GM1 and GA1, there are other glycoconjugates that contain β-linked galactose whose metabolites are substrates for β-galactosidase. For example, a number of N-linked glycan structures that have galactose at their non-reducing end have been shown to accumulate in GM1 gangliosidosis patient tissues and biological fluids. Objective: In this study, we attempt to fully characterize the broad array of GLB1 substrates that require GLB1 for their lysosomal turnover. Results: Using tandem mass spectrometry and glycan reductive isotope labeling with data-dependent mass spectrometry, we have confirmed the accumulation of glycolipids (GM1 and GA1) and N-linked glycans with terminal beta-linked galactose. We have also discovered a novel set of core 1 and 2 O-linked glycan metabolites, many of which are part of structurally-related isobaric series that accumulate in disease. In the brain of GLB1 null mice, the levels of these glycan metabolites increased along with those of both GM1 and GA1 as a function of age. In addition to brain tissue, we found elevated levels of both N-linked and O-linked glycan metabolites in a number of peripheral tissues and in urine. Both brain and urine samples from human GM1 gangliosidosis patients exhibited large increases in steady state levels for the same glycan metabolites, demonstrating their correlation with this disease in humans as well. Conclusions: Our studies illustrate that GLB1 deficiency is not purely a ganglioside accumulation disorder, but instead a broad oligosaccharidosis that include representatives of many β-linked galactose containing glycans and glycoconjugates including glycolipids, N-linked glycans, and various O-linked glycans. Accounting for all β-galactosidase substrates that accumulate when this enzyme is deficient increases our understanding of this severe disorder by identifying metabolites that may drive certain aspects of the disease and may also serve as informative disease biomarkers to fully evaluate the efficacy of future therapies. |
publishDate |
2019 |
dc.date.accessioned.fl_str_mv |
2019-12-28T04:01:26Z |
dc.date.issued.fl_str_mv |
2019 |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/203968 |
dc.identifier.issn.pt_BR.fl_str_mv |
2214-4269 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001109125 |
identifier_str_mv |
2214-4269 001109125 |
url |
http://hdl.handle.net/10183/203968 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Molecular genetics and metabolism reports. New York. vol. 21 (Dec. 2019), 100524, 17 f. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/203968/2/001109125.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/203968/1/001109125.pdf |
bitstream.checksum.fl_str_mv |
12c4d5094c6c76b42ea6c01b5fa048ae bd1d0098916bf1fda3132a982f53e23c |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224981702508544 |